Healionics
Healionics develops vascular grafts and biomaterial scaffolds for safer and more reliable bloodstream access in dialysis patients with kidney failure. Its STARgraft vascular graft is designed to resist occlusion and infection, aiming to improve patient health and reduce the cost of dialysis care. The company’s STAR biomaterial platform supports tissue regeneration while minimizing scarring and infection in implantable devices.
Facts
- HQ
- Seattle, WA
- Sectors
- Medical Device
- Founded
- 2007
- Type
- Corporation Seattle business license
- Employees
- 9
- Registered name
- Healionics Corp Seattle business license
- Members see funding amounts. .
Is this your organization? Claim it
UW College of Engineering Retrospective Highlights CoMotion-Supported Innovations in Health, Transit, and Materials
The UW College of Engineering highlighted transformative technologies developed by researchers supported by CoMotion, including smartphone health screening tools and the OneBusAway app, with ongoing innovations like Healionics' dialysis grafts. These advances have impacted health care, transportation, computing, and materials.
Healionics Raises $5.5M to Complete Human Trial of STARgraft Artificial Blood Vessel for Dialysis Patients
Healionics, a Seattle-based medical tech company, raised $5.5 million to complete human trials and pursue regulatory approval for its STARgraft artificial blood vessel designed for dialysis patients. The STARgraft aims to provide a durable vascular access solution resistant to blockages and infections that commonly affect dialysis patients.
Healionics raises $4.7M led by Keiretsu Capital to commercialize STARgraft artificial blood vessel, aims for early‑next‑year launch
Seattle medical device company Healionics raised $4.7 million led by Keiretsu Capital to commercialize STARgraft, a synthetic vascular graft designed to resist occlusion for dialysis patients, and plans a commercial launch early next year. The funding will finance a second human study and FDA clearance efforts; the company also converted $5.2 million of notes and interest into equity.
People
-
Andrew Marshall Executive, Director & Chief Technology Officer
-
Max Maginness Executive, President & Chief Operating Officer
-
Mike Connolly Executive, CEO & Chairman
Online
Questions about Healionics
What is Healionics?
Healionics is a former startup based in Seattle, WA that develops vascular grafts and biomaterial scaffolds for bloodstream access in dialysis patients with kidney failure.
What is Healionics known for?
Healionics is known for STARgraft, a vascular graft designed to resist occlusion and infection, and its STAR biomaterial platform, which supports tissue regeneration while minimizing scarring and infection in implantable devices.
What has Healionics been in the news for?
GeekWire reported in February 2024 on Healionics’ plans to complete a human trial of STARgraft, an artificial blood vessel for dialysis patients. GeekWire reported in May 2021 on plans to commercialize STARgraft, with a launch targeted for early the following year.
Who are the people behind Healionics?
Mike Connolly is CEO and chairman at Healionics, Max Maginness is president and chief operating officer, and Andrew Marshall is director and chief technology officer.
Who invested in Healionics, and how much has it raised?
Members of Seattle Flow see Healionics' funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Healionics based?
Healionics is based in Seattle, WA.